Singapore, Aug 18, 2010: Australian pharma company, QrxPharma's lead compound MoxDuo IR, has been awarded the 2010 North American Frost & Sullivan Award for New Product Innovation of the Year. Frost and Sullivan, a global research and market analysis firm, has awarded this in culmination of their comprehensive analysis of the opioid pain management market.

“We are honoured to receive this prestigious award which recognizes the potential of our patented Dual Opioid technology in terms of the benefits it will deliver to patients, by offering superior pain relief with fewer side effects than competing products.” said Dr John Holaday, managing director, QRxPharma. “Frost & Sullivan’s assessment of the opioid pain management highlights the limitations of existing therapies and validates the opportunity for MoxDuo to become a major player in this market which is over $7 billion annually in the US alone.”